Science and Research

Case report: Incidental MALT lymphoma of the left adrenal gland mimicking a metastatic spread within durvalumab maintenance treatment in inoperable stage III non-small cell lung cancer

Durvalumab after chemotherapy in non-operable stage III non-small cell lung cancer (NSCLC) is the standard of care worldwide. We present a patient with the incidental discovery of a unilateral MALT lymphoma of the adrenal gland and adrenalitis during durvalumab maintenance treatment detected by 18F-FDG-PET/CT. We assessed the clinical and histopathological findings, radiological examinations and overall treatment. Our work emphasizes the significance of considering other differential diagnoses and the importance of multidisciplinary treatment of the findings, especially within clinical trials.

  • Käsmann, L.
  • Degerli, E.
  • El-Marouk, K.
  • Manapov, F.

Keywords

  • MALT lymphoma
  • Nsclc
  • Pet/ct
  • durvalumab
  • immune-related side effect
Publication details
DOI: 10.3389/fonc.2024.1226422
Journal: Front Oncol
Pages: 1226422 
Work Type: Original
Location: CPC-M
Disease Area: LC
Partner / Member: KUM
Access-Number: 38567155

DZL Engagements

chevron-down